דוסיטקסל טבע ® תמיסה מרוכזת בבקבוקון יחיד

Valsts: Izraēla

Valoda: ivrits

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

DOCETAXEL 20 MG/ML

Pieejams no:

ABIC MARKETING LTD

ATĶ kods:

L01CD02

Zāļu forma:

CONCENTRATE FOR SOLUTION FOR INFUSION

Ievadīšanas:

I.V

Ražojis:

PHARMACHEMIE B.V., THE NETHERLANDS

Ārstniecības grupa:

DOCETAXEL

Ārstēšanas norādes:

Breast cancer: Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline

Autorizācija datums:

2013-06-01